| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | Oxyntomodulin (dual GLP-1/glucagon analog) Metabolic and fibrotic disorders | Phase 1 | — | Peptides | Endocrine System | ||
phase 1 data readout example | Oxyntomodulin (dual GLP-1/glucagon analog) Metabolic and fibrotic disorders | Phase 1 | — | Peptides | Endocrine System | ||
phase 1 data readout example | Oxyntomodulin (dual GLP-1/glucagon analog) Metabolic and fibrotic disorders | Phase 1 | — | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Opko Health Inc.$1.41
+0.02 (+1.08%)
B 74Pipeline Score Undervalued Biotech · Commercial
Market Cap
880.52 M
EPS
-0.30
P/E Ratio
-3.84 $
Value Trade
6.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
124.20 M
R&D Expenses
29.20 M
Operating CF
-19.31 M
Total Assets
1.86 B
Total Liabilities
652.19 M
Equity
1.20 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
331.86 M
Monthly Burn
6.44 M
Runway
50.2 mo
Burn Trend
SEC Filing
Apr 28, 2026
Overview
Volume
613.23 K
52 Week Range
1.10 - 1.60
% held by Insiders
50.3 %
% held by Institutions
28.31 %
Enterprise Value
908.23 M
Total Shares
758.89 M
Short %
10.01 %
Float Shares
330.12 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B74
Pipeline Score $13.2B
Pipeline ValueUndervalued
Valuation Signal22
Drugs Scored15.0x
rNPV / MCap Top 96%
Micro Cap (rank 37 of 905)
Percentile RankOpko Health Inc. holds a solid B-grade pipeline (74/100), with $52.0B risk-adjusted pipeline value, led by CTAP101 30 μg in Chronic Kidney Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTAP101 30 μg Small molecule | Chronic Kidney Disease | Phase 3 | NCT01704079 | 60% | $14.7B | COMPLETED | 429 | - | - | Sep 1, 2014 | - | Jan 13, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OPK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Opko Health Inc. (OPK) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
OPK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OPK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OPK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OPK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
OPK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OPK
Jun 15, 2026Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Biologics presented promising preclinical data for OPK8801001 at ENDO 2026, indicating its potential as a long-acting treatment for acromegaly. The data demonstrated significant suppression of IGF-1 levels, suggesting a weekly dosing alternative to current daily therapies. The findings reinforce OPKO's commitment to developing innovative treatment options for patients with endocrine disorders.
Read more →-OPK
Apr 30, 2026BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
BioReference Health LLC has launched BioReference Direct, a digital platform that allows consumers to access laboratory testing directly. This initiative aims to enhance patient-driven healthcare by providing a seamless online experience for selecting tests. The platform includes various health panels and an at-home STI test in collaboration with Abbott, promoting early detection and proactive health management.
Read more →-OPK
Apr 29, 2026OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the first quarter of 2026. The company reaffirmed its financial guidance for the year and scheduled a conference call to discuss these results. However, the report included cautionary forward-looking statements regarding product development and regulatory challenges.
Read more →-OPK
Feb 27, 2026OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. will participate in the Jefferies Biotech on the Beach Summit on March 10-11, 2026, at 1 Hotel South Beach in Miami. The company plans to hold one-on-one meetings with registered investors on March 11. This engagement aims to strengthen investor relations and showcase OPKO's biopharmaceutical and diagnostics expertise.
Read more →-OPK
Feb 12, 2026OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. plans to report its financial results for Q4 2025 on February 26, 2026. The announcement includes a conference call where senior management will discuss the results and provide financial guidance. Participants can pre-register for easier access to the call, which will also be available via webcast.
Read more →-OPK
Feb 4, 2026OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
OPKO Health and Entera Bio have expanded their partnership to develop a first-in-class oral long-acting PTH tablet for hypoparathyroidism. The companies plan to file an IND application with the FDA in late 2026, following promising preclinical data. This collaboration aims to provide a more convenient treatment option for patients, moving away from daily injections.
Read more →Competitive Position
How OPK ranks across every disease it competes inCompetitive Position is a premium feature
See how OPK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial